Genetic markers of schizophrenia endophenotypes
This document provides methods and materials related to genetic markers of schizophrenia (SZ), schizotypal personality disorder (SPD), and/or schizoaffective disorder (SD), (collectively referred to herein as “schizophrenia spectrum disorders” or SSDs). For example, methods for using such genetic markers to identify an SSD (e.g., SZ) endophenotype are provided.
1. A method of determining likelihood of having a schizophrenia (SZ) endophenotype in a human subject, the method comprising:
obtaining a sample comprising genomic DNA of the subject;
determining the presence of an A allele at rs2779400 in the sample;
wherein the presence of an A allele at rs2779400 indicates that the subject is more likely to have a schizophrenia endophenotype of a lower PANSS Total composite score, a lower PANSS General Psychopathology composite score, a lower G3 score, and a lower G13 score, as compared to a subject who does not have an A allele at rs2779400.
2. The method of claim 1 , wherein determining the identity of the nucleotide comprises contacting the sample with a probe specific for a selected allele of the polymorphism, and detecting the formation of complexes between the probe and the selected allele of the polymorphism, wherein the formation of complexes between the probe and the test marker indicates the presence of the selected allele in the sample.
3. The method of the claim 1 , wherein determining the identity of an allele comprises determining the identity of the nucleotide at position 31 of SEQ ID NO:66.
4. The method of claim 1 , wherein the subject is a patient having or suspected of having SZ.
5. The method of claim 1 , wherein the subject has one or more risk factors associated with SZ.
6. The method of claim 5 , wherein the risk factors associated with SZ include one or more of: a relative afflicted with a schizophrenia spectrum disorder (SSD); and a genetically based phenotypic trait associated with risk for a SSD.
7. The method of claim 1 , further comprising selecting or excluding a subject for enrollment in a clinical trial based on the identity of the allele.
8. The method of claim 1 further comprising stratifying a subject population for analysis of a clinical trial based on the identity of the allele in the subjects.
9. The method of claim 1 , further comprising confirming a severity of a SZ endophenotype using psychometric instruments.
10. The method of claim 1 , further comprising recording the identity of the allele in a tangible medium.
11. The method of claim 10 , wherein the tangible medium comprises a computer-readable disk, a solid state memory device, or an optical storage device.